Ascendiant Capital Markets Comments on Pro-Dex FY2026 Earnings

Pro-Dex, Inc. (NASDAQ:PDEX) – Equities research analysts at Ascendiant Capital Markets issued their FY2026 earnings per share estimates for shares of Pro-Dex in a research report issued on Monday, May 11th. Ascendiant Capital Markets analyst E. Woo anticipates that the medical instruments supplier will post earnings per share of $3.16 for the year. Ascendiant Capital Markets has a “Buy” rating and a $70.00 price objective on the stock.

Pro-Dex (NASDAQ:PDEX) last issued its quarterly earnings results on Thursday, April 30th. The medical instruments supplier reported $1.20 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.62 by $0.58. The firm had revenue of $19.95 million during the quarter, compared to analyst estimates of $17.90 million. Pro-Dex had a return on equity of 22.78% and a net margin of 16.08%.

Separately, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Pro-Dex in a research note on Friday, May 1st. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, Pro-Dex currently has a consensus rating of “Moderate Buy” and an average target price of $70.00.

Pro-Dex Stock Performance

Shares of NASDAQ PDEX opened at $60.78 on Wednesday. The stock has a fifty day moving average price of $51.67 and a two-hundred day moving average price of $43.53. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.14 and a current ratio of 3.67. The firm has a market cap of $193.89 million, a P/E ratio of 16.79 and a beta of -0.12. Pro-Dex has a 1 year low of $23.47 and a 1 year high of $62.15.

Institutional Investors Weigh In On Pro-Dex

Several large investors have recently modified their holdings of the stock. Corsair Capital Management L.P. bought a new stake in shares of Pro-Dex during the 1st quarter worth $532,000. Punch & Associates Investment Management Inc. boosted its stake in shares of Pro-Dex by 2.9% during the 1st quarter. Punch & Associates Investment Management Inc. now owns 61,735 shares of the medical instruments supplier’s stock worth $3,032,000 after acquiring an additional 1,735 shares in the last quarter. Morgan Dempsey Capital Management LLC boosted its stake in shares of Pro-Dex by 6.2% during the 1st quarter. Morgan Dempsey Capital Management LLC now owns 5,808 shares of the medical instruments supplier’s stock worth $286,000 after acquiring an additional 339 shares in the last quarter. Quadrature Capital Ltd bought a new stake in shares of Pro-Dex during the 4th quarter worth $220,000. Finally, Osaic Holdings Inc. boosted its stake in shares of Pro-Dex by 44.8% during the 4th quarter. Osaic Holdings Inc. now owns 11,434 shares of the medical instruments supplier’s stock worth $440,000 after acquiring an additional 3,540 shares in the last quarter. 15.28% of the stock is owned by institutional investors.

About Pro-Dex

Pro-Dex, Inc is a designer and manufacturer of precision drive systems and fluid management products serving the dental, medical, industrial and energy markets. The company specializes in high-speed, brushless micromotors and controllers, as well as pneumatic and fluid control devices, providing both standard and custom-engineered solutions for original equipment manufacturers.

Its product portfolio includes high-speed dental handpieces, turbine systems, rotary and reciprocating micro-drives, along with integrated fluid delivery systems.